3:58 PM
 | 
Sep 21, 2012
 |  BC Extra  |  Clinical News

Menarini reports Phase II data for ibodutant

Menarini Group (Florence, Italy) reported top-line data showing that once-daily 10 mg ibodutant met both the EMA and FDA primary endpoints in the Phase II IRIS-2 trial to treat irritable bowel syndrome with diarrhea (IBS-D). Specifically, a significantly...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >